Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.
References:
[1]. Jonas S Heitmann, et al. Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives. Cancers (Basel). 2021 Feb 1;13(3):549.
















